ACE inhibitors and proteinuria

Pharmacy World and Science

Volumn 18, Issue 6, 1996, Pages 204-210

  Gansevoort, R T ^a   De Zeeuw, D ^b   De Jong, P E ^b  

^a TWENTEBORG HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

albuminuria; angiotensin II; angiotensin converting enzyme inhibitors; bradykinin; glomerular filtration rate; nephrotic syndrome; proteinuria; renal circulation; review

Indexed keywords

ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; DRUG MECHANISM; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PROTEINURIA; REVIEW; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; PROTEINURIA;

EID: 0030473856     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00735961     Document Type: Review

References (81)

1. Prins, E.J.L, Hoorntje, S.J., Weening, J.J., Donker, A.J.M.: Nephrotic syndrome in a patient on captopril, Lancet 1979;ii:306.
2. Hoorntje, S.J., Weening, J.J., Kallenberg, C.G.M., Donker, A.J.M.: serum-sickness-like syndrome with membranous glomerulopathy in patients on captopril, Lancet 1979;ii:1297.
3. Hoorntje, S.J., Weening, J.J., Prins, E.J.L, Donker, A.J.M.: Membranous glomerulopathy in a patient on captopril, Acta Med Scand 1980;208:325.
4. Case, D.B., Atlas, S.A., Mouradian, J.A., Fishman, R.A., Sherman, R.L, Laragh, J.H.: Proteinuria during long-term captopril therapy, JAMA 1980;244:346-349.
5. Sturgill, B.C., Shearlock, K.T.: Membranous glomerulopathy and nephrotic syndrome after captopril therapy, JAMA 1983;250:2343-2345.
6. Isles, C.G., Hodsman, G.P., Robertson, J.I.S.: Side-effects of captopril, Lancet 1983;i:355.
7. Captopril Collaborative Study Group: Does captopril cause renal damage in hypertensive patients? Lancet 1982;i:988-990.
8. Groel, J.I., Todros, S.S., Dreslinski, G.R., Jenkins, A.C.: Long-term antihypertensive therapy with captopril, Hyperten 1983;145 (S3):5.
9. Simon, G., Morioka, S., Snyder, D.K., Cohn, J.N.: Increased renal plasma flow in long-term enalapril treatment of hypertension, Clin Pharmacol Ther 1983;34:459-465.
10. Herlitz, H., Edeno, C., Mulec, H., Westberg, G., Aurell, M.: Captopril treatment of hypertension and renal failure in systemic lupus erythematosus, Nephron 1984;38:253-256.
11. Taguma, Y., Kitamoto, Y., Futaki, G., Ueda, H., Monma, H., Ishizaki, M.: Effect of captopril on heavy proteinuria in azotemic diabetes, N Engl J Med 1985;313:1617-1620.
12. Heeg, J.E., de Jong, P.E., van de Hem, G.K., de Zeeuw, D.: Reduction of proteinuria by angiotensin converting enzyme inhibition, Kidney Int 1987;32:78-83.
13. Brazy, P.C., Stead, W.W., fitzwilliam, J.F.: Progression of renal insufficiency: Role of blood pressure, Kidney Int 1989;35:670-674.
14. Viberti, G.C.: Prognostic significance of microalbuminuria, Am J Hypertens 1994;7:69s-72s.
15. Hunt, L.P., Short, Cd., Mallick, N.P.: Prognostic indicators in patients presenting with the nephrotic syndrome, Kidney Int 1988;34:382-388.
16. Williams, P.S., Fass, G., Bone, J.M.: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure, QJ Med 1988;67:343-354.
17. Klahr. S., Levey, A.S., Beck, G.J., Gaggiula, A.W., Hunsicker, L., Kusek, J.W., Striker, G.: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease, New Engl J Med 1994;330:877-884.
18. Remuzzi, G., Bertani, T.: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384-394.
19. Samuelsson, O., Wilhelmsen, L., Elmferdt, D., Pennert, K., Wedel, H., Widstrand, J., Berglund, G.: Predictors of cardiovascular morbidity in treated hypertension, results from the primary preventive trial in Goteborg, Sweden, J Hypertens 1985;3:167-176.
20. Kannel, W.B., Stampfer, M.J., Castelli, W.P., Verter, J.: The prognostic significance of proteinuria, The Framingham Study, Am Heart J 1984;108:1347-1352.
21. Bulpitt, C.J., Beevers, D.G., Butler, A., Coles, E.C., Hunt, D., Munro-Faure, a.D., Newson, R.B.: The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP), J Hypertensl 986;4:93-99.
22. Yudkin, S.J., Forrest, R.D., Jackson, C.: Microalbuminuria as a predictor of vascular disease in non-diabetic subjects, Lancet 1988;ii:530-533.
23. Damsgaard, E.M., Froland, A., Jorgensen, Mogensen, C.E.: Microalbuminuria as predictor of increased mortality in elderly people, Br Med J 1990;300:297-300.
24. Samuelsson, O.: Proteinuria as a prognostic factor during long term hypertensive care, Drugs, 35, S5 48-54,1988.
25. Ritz, E., Nowicki, M., Flisler, D., Horner, D., Klimm, H.P.: Proteinuria and hypertension. Kidney Int 1994;46:S47,S76-S80.
26. Mogensen, C.E.: Micro-albuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes, N Engl J Med 1986;310:356-360.
27. Jarret, R.J., Viberti, G.C., Argyropoulos, A., Hill, R.D., Mahmud, U., Murrels, T.J.: Microalbuminuria predicts mortality in non-insulin dependent diabetes, Diabetic Med 1984;1:17-19.
28. Schmitz, A., Vaeth, M.: Micro-albuminuria: a major risk factor in non insulin dependent diabetes. A 10 year follow-up of 503 patients, Diabetic Med 1988;5:126-134.
29. Ordonez, J.d., Hiatt, R.A., Killebrew, E.J., Firmena, B.H.: The increased risk of coronary heart disease associated with nephrotic syndrome, Kidney Int 1993;44:638-642.
30. Gansevoort, R.T, Sluiter, W., Hemmelder, M.H., de Zeeuw, D., de Jong, P.E.: The antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials, Neprhol Dial Transplant 1995 (in press);10:11.
31. Fioretto, P., Frigato, F., Velussi, M., Riva, F., Muollo, B., Carraro, A.: Effects of angiotensin converting enzyme inhibtors and calcium antagonists on atrial natriuretic peptide release and action on albumin excretion rate in hypertensive insulin-dependent diabetic patients, Am J Hypertens 1992;5:37-846.
32. Demarie, B.K., Bakris, G.L.: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus, Annals Int Med 1990;113:987-988.
33. Wight, J.P., Brown, C.B., El Nahas, A.M.: Short-term effects of calcium antagonists on renal hemodynamics in patients with chronic renal failure, Nephron 1991;58:62-67.
34. Kasiske, B.L, Kalil, R.S.N., Ma, J.Z., Liao, M., Keane, W.F.: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis, Annals Int Med 1993;118:129-138.
35. Weidmann, P., Boehlen, LM., de Courten, M.: Effects of different antihypertensive drugs on human diabetic proteinuria, Neprhol Dial Transplant 1993;8:582-584.
36. Anderson, S., Meyer, T.W., Rennke, H.G., Brenner, B.M.: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass, J Clin Invest 1985;76:612-619.
37. Arisz, L, Donker, A.J.M., Brentjens, J.R.H., van der Hem, G.K.: The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome, Acta Med Scand 1976;199:122-125.
38. Donker, A.J.M., Brentjens, J.R.H., van der Hem, G.K., Arisz, L: Treatment of the nephrotic syndrome with indomethacin, Nephron 1978;22:374-381.
39. Rosenberg, M.E., Swanson, J.E., Thomas, B.L, Hosteller, T.H.: Glomerular and hormonal responses to dietary protein intake in human renal disease, Am J Physiol 1987;253:F1083-F1090.
40. Wetzels, J.F.M., Hoitsma, A.J., Berden, J.H.M., Koene, R.A.P.: Renal hemodynamic effects of a short-term high protein and low protein diet in patients with renal disease, Clin Neprhol 1988;30:42-47.
41. Olmer, M., Pain, C., Dussol, B., Berland, Y.: Protein diet and nephrotic syndrome, Kidney Int 1989;36:S152-S13.
42. Heeg, J.E., de Jong, P.E., de Zeeuw, D.: Additive antiproteinurelic effect of angiotensin converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action, Clinical Science 1991 ;81:367-372.
43. Gansevoort, R.T., de Zeeuw, d., de Jong, P.E.: Additive antiproteinuretic effect of ACE inhibition and a low protein diet in human renal disease, Nephrol Dial Transplant 1995;10:497-504.
44. Ruilope, LM., Casai, M.C., Praga, M., Alcazar, J.M., Decap, G., Lahera, V., Rodicio, J.L.: Additive antiproteinuric effect of converting enzyme inhibition and a low protein intake, J. Am Soc Nephrol 1992;3:1307-1311.
45. Allon, M., Pasque, Cb., Rodriguez, M.: Acute effects of captopril and ibuprofen in patients with nephrosis, J Lab Clin Med 1990;116:462-468.
46. Heeg, J.E., de Jong, P.E., van der Hem, G.K., de Zeeuw, D.: Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhbition, Kidney Int 1991;40:734-741.
47. Gansevoort, R.T., de Zeeuw, D., de Jong, P.E.: Dissociation between the course of the hemodynamic and antiproteinuric effects of ACE inhibition, Kidney Int 1993;44:579-584.
48. Gibbons, G.H., Dzau, V.J.: the emerging concept of vascular remodelling, New Engl J Med 1994;330:1431-1438.
49. Wolf, G., Neilson, E.G.: Angiotensin II as a renal growth factor, J Am Soc Nephrol 1993;3:1531-1540.
50. Dorer, F.E., Kahn, J.R., Lentz, K.E., Levine, M., Skeggs, L.T.: Hydrolysis of bradykinin by angiotensin converting enzyme, Circ Res 1974;34:824-827.
51. Israilli, Z.H., Hall, W.D.: Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy, Ann Intern Med 1992;117:234-242.
52. Gavras, I.: Bradykinin mediated effects of ACE inhibition. Kidney Int 1992;42:1020-1029.
53. Hutchison, F.N., Martin. V.I.: Effects of modulation of renal kallikrein-kinin system in the nephrotic syndrome, Am J Physiol 1990;258:F1237-F1244.
54. Fenoy, F.J., Scicli, G., Carretero, O., Roman, R.J.: Effects of an angiotensin Il and a kinin receptor antagonist on the renal hemodynamic response to captopril, Hypertension 1991;17:1038-1044.
55. Hajj-Ali, A.F., Zimmerman, B.C.: Kinin contribution to renal vasodilator effect of captopril in rabbits, Hypertension 1991;17:504-509.
56. Gansevoort, R.T., de Zeeuw, D., de Jong, P.E.: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin angiotensin system? Kidney Int 1994;45:861-867.
57. Rhaleb, N.E., Rouissi, N., Nantel, F., D'Orleans-Juste, P., Regoli, D.: Dup 753 is a specific antagonist for the angioten-sin receptor, Hypertension 1991;17:480-484.
58. Heeg, J.E., de Jong, P.E., van der Hem, G.K., de Zeeuw, D.: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril, Kidney Int 1989;36:272-279.
59. Gansevoort, R.T., de Zeeuw, D., de Jong, P.E.: Long-term benefits of the antiproteinuric effect of ACE inhibition in nondiabetic renal disease, Am J Kidney Dis 1993;2:202-206.
60. Buter, H., Hemmelder, M.H., de Zeeuw, D., de Jong, P.E.: HCT potentiates the effect of ACE inhibition comparable to a low sodium diet, J Am Soc Nephrol 1995;6:420.
61. Knaus, W.A., Wagner, D.P., Draper, E.A., Zimmerman, J.E., Bergman, M., Bastos, P.C.: The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults, Chest 1991;100:1619-1636.
62. Marik, P.E.: The treatment of hypoalbuminemia in the critically ill patient, Heart Lung 1993;22:166-170.
63. Appel, G.B., Blum, C.B., Chien, S., Kunis, C.L., Appel, A.S.: the hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure and viscosity, N Engl J Med 1985;312:1544-1548.
64. Joven, J., Villabona, C., Vilella, E., Masana, L, Alberti, R., Valles, M.: Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome, N Engl J Med 1990;323:579-584.
65. Karadi, O., Romics, L., Palos, G., Doman, J., Kaszas, I., Hesz, A., Kostner, G.M.: Lp (a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin, Clin Chem 1989;35:2121-2123.
66. Keilani, T., Schlueter, W.A., Levin, M.L, Gatlle, D.C.: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor, Annals Int Med 1993;118:246-254.
67. Keane, W.F., Kasiske, B.L.: Hyperlipidemia in the nephrotic syndrome, N Engl J Med 1990;323:603-604.
68. Wanner, C, Bohler, J., Eckhardt, H.G., Wieland, H., Schollmeyer, P.: Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome, Clin Nephrol 1993;in press:39.
69. Gansevoort, R.T., Heeg, J.E., Dikkeschei, B.D., de Zeeuw, d., de Jong, P.E., Dullaart, R.P.F.: Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria, Nephrol Dial Transplant 1994;9:244-250.
70. Rabelink, A.J., Hene, R.J., Erkelens, D.W., Joles, J.A., Koomans, H.A.: Effect of simvastatin and cholestyramine on lipoprotein profile in hyperlipidemia of nephrotic syndrome, Lancet 1988;ii:1335-1338.
71. Thomas, M.E., Freestone, A., Varghese, Z., Persaud, J.W., Moorhead, J.M.: Lipoprotein (a) in patients with proteinuria, Neprhol Dial Transplant 1992;7:597-601.
72. Warwick, G.L., Packard, C.J., Murray, L., Grierson, D., Stewart, J.P., Shepherd, J., Boulton-Jones, J.M.: Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome. Clinical Science 1992;82:701-708.
73. Bjorck, S., Nyberg, g., Mulec, H., Granerus, G., Herlitz, H., Aurell, M.: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy, Br Med J 1986;293:471-474.
74. Parving, H.H., Andersen, A.R., Smidt, U.M., Hommel, E., Mathiesen, E.R., Svendsen, P.A.: Effect of antihypertensive teatment on kidney function in diabetic nephropathy, Br Med J 1987;294:1443-1447.
75. Brazy, P.C., Fitzwilliam, J.F.: Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990;37: 1113-1119.
76. Lewis, E.J., Hunsicker, LG., Bain, R.P., Rohde, R.D.: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy, N Engl J Med 1993;329:1456-1462.
77. Hannedouche, T., Landais, P., Goldfarb, B., El Esper, N., Fournier, a., Godin, M., Durand, D., Chanard, J., Mignon, F., Suc, J-M., Grunfeld, J.P.: Randomised controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure, BMJ 1994;309:833-837.
78. Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann J.F.E., Motolese, M., Ponticelli, C., Ritz, E., Zuchelli, P.: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med 1996 1996;334:939-945.
79. Praga, M., Hernandez, E., Montoyo, C., Andres, A., Ruilope, L.M., Rodicio, J.L.: Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria, Am J Kidney Dis 1992;20:240-248.
80. Rossing, P., Hommel, E., Smidt, U.M., Parving, H.H.: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994;45:S145-S149.
81. Apperloo, A.J., de Zeeuw, D, de Jong, P.E.: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease, Kidney Int 1994;45:S174-S178.